title: [Antimicrobial prophylaxis in transurethral resection of the prostate].
abstract: OBJECTIVE
  A prospective trial was performed to propose a suitable antimicrobial prophylaxis in patients undergoing transurethral resection of the prostate (TUR-P).
  
  
  METHODS
  Patients who underwent TUR-P due to symptomatic prostatic hyperplasia between April 1995 and February 1996 were included. Based on the results of urinalysis obtained within preoperative 3 days, the patients were classified into Group I (less than 5 WBC/hpf and bacterial count of less than 10(4) CFU/ml in urine specimen), and Group II (5 or more WBC/hpf or bacterial count of 10(4) or more CFU/ml in urine specimen). Furthermore, each group was randomly subdivided into Group A and Group B according to the period of antimicrobial administration. As prophylactic antimicrobials, cefazolin (CEZ) was used in Group I and CEZ or cefotiam (CTM) in Group II. The antimicrobial was administered only on the day of operation in Group IA (n = 92), for 3 days in Group IB (n = 96), 2 days in Group IIA (n = 37), and 4 days in Group IIB (n = 30). On the day of operation, the antimicrobial was infused immediately before the operation. The presence or absence of pyuria, bacteriuria and febrile infection, and the period required for normalization of the urinalysis were the major points evaluated here.
  
  
  RESULTS
  No significant differences were observed in any parameters with respect to the period of administration of antimicrobial between the groups, but in both Group I and Group II, the incidence of febrile infection was higher in the groups with shorter antimicrobial administration periods. The mean period for normalization of the urinalysis required 68.4, 68.6, 65.2 and 58.2 days in Group IA, Group IB, Group IIA and Group IIB, respectively.
  
  
  CONCLUSIONS
  It is concluded that 3 or 4-day administration of first or second generation parenteral cephems is generally acceptable regimen for antimicrobial prophylaxis in patients undergoing TUR-P.
authors.affiliation: Department of Urology, Okayama University Medical School.
authors.forename: M
authors.initials: M
authors.lastname: Tsugawa
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: K
authors.initials: K
authors.lastname: Monden
authors.forename: H
authors.initials: H
authors.lastname: Kumon
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
mesh_terms: D000368:Aged; D019072:Antibiotic Prophylaxis; D002437:Cefazolin / Q000627:therapeutic use*; D015310:Cefotiam / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000382:microbiology / Q000601:surgery; D014552:Urinary Tract Infections / Q000517:prevention & control
chemical_list: D002511:Cephalosporins; D015310:Cefotiam; D002437:Cefazolin